Targets › DPP3
1 program from 1 company in 1 trial: 1 Phase 1; Other; next expected readout Dec 2026.
Cleaves and degrades bioactive peptides, including angiotensin, Leu-enkephalin and Met-enkephalin. Also cleaves Arg-Arg-beta-naphthylamide (in vitro). (UniProt, Q9NY33)
Open in Phaseline: the race on DPP3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| 4TEEN4 Pharmaceuticals | AK1967 (Invobenitug also known as Procizumab) DPP3 inhibition using humanized monoclonal antibody | DPP3 | Phase 1 | Shock, Cardiogenic | Dec 2026 |
Shock, Cardiogenic (1)
antibody (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.